Search

Your search keyword '"Eric A. Singer"' showing total 40 results
Start Over Author "Eric A. Singer" Journal journal of urology
40 results on '"Eric A. Singer"'

1. MP63-05 OUTCOMES IN PATIENTS (PTS) WITH BACILLUS CALMETTE-GUERIN (BCG)-UNRESPONSIVE HIGH-RISK (HR) NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC) WHO UNDERWENT RADICAL CYSTECTOMY (RC) FOLLOWING PEMBROLIZUMAB (PEMBRO) TREATMENT IN KEYNOTE-057 COHORT A

Author

Girish S. Kulkarni, Ashish M. Kamat, Edward M. Uchio, Mathieu Roumiguié, Laurence E. M. Krieger, Eric A. Singer, Dean F. Bajorin, Petros Grivas, Ho Kyung Seo, Hiroyuki Nishiyama, Badrinath R. Konety, Ronald de Wit, Ekta Kapadia, Aiwen Xing, Margot Van den Sigtenhorst Fijlstra, and Joost L. Boormans

Subjects
Urology
Published
2023

3. PD41-03 ANTIBIOTIC-FREE TRANSPERINEAL PROSTATE BIOPSY: UROLOGY’S CONTRIBUTION TO RESPONSIBLE ANTIMICROBIAL STEWARDSHIP

Author

Kevin B. Ginsburg, Johnathan Drevik, Jared P. Schober, Alberto A. Castro Bigalli, Jeffrey L. Ellis, Avery Braun, Kaynaat Syed, John Danella, Serge Ginzburg, Laurence Belkoff, Adam C. Reese, Jeffrey Tomaszewski, Edouard Trabulsi, Eric A. Singer, Bruce Jacobs, Jay D. Raman, Thomas Guzzo, Robert G. Uzzo, Marc C. Smaldone, and Andres F. Correa

Subjects
Urology
Published
2022

4. PD53-11 RISK STRATIFICATION IN ADVANCED NON-SEMINOMATOUS GERM CELL TUMORS (NSGCT): VALIDATION OF AGE AND METASTATIC DISEASE SITE TO IMPROVE THE TRADITIONAL IGCCCG RISK GROUPS

Author

Marcus L. Quek, Solomon L. Woldu, Phillip M. Pierorazio, Thomas L. Jang, Aditya Bagrodia, Nirmish Singla, Arnav Srivastava, Joseph G. Cheaib, Eric A. Singer, Isaac Yi Kim, Hiten D. Patel, Gopal N. Gupta, and Hiren V. Patel

Subjects
Oncology, medicine.medical_specialty, Risk groups, business.industry, Urology, Internal medicine, Risk stratification, medicine, Germ cell tumors, Disease, medicine.disease, business
Published
2021

5. MP05-04 CLINICALLY SIGNIFICANT PROSTATE CANCER DETECTION RATES ON MRI GUIDED FUSION NEEDLE BIOPSY - EXPERIENCE FROM THE PENNSYLVANIA UROLOGIC REGIONAL COLLABORATIVE

Author

Ako Adams Ako, Laurence Belkoff, Robert G. Uzzo, Bruce L. Jacobs, Serge Ginzburg, Edouard J. Trabulsi, John Danella, Jay D. Raman, Adam C. Reese, Eric A. Singer, Claudette Fonshell, Thomas J. Guzzo, and Jeffery Tomaszewski

Subjects
medicine.medical_specialty, medicine.diagnostic_test, business.industry, Urology, 030232 urology & nephrology, Magnetic resonance imaging, medicine.disease, 3. Good health, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, 030220 oncology & carcinogenesis, Needle biopsy, medicine, Radiology, Detection rate, business, Systematic biopsy, Mri guided
Abstract

INTRODUCTION AND OBJECTIVE:Magnetic resonance imaging (MRI) fusion needle biopsy has been shown to outperform systematic biopsy in detecting clinically significant prostate cancer. This study sough...

Published
2021

6. MP19-08 DISPARITIES IN CLINICAL TRIAL PARTICIPATION FOR PATIENTS WITH RENAL CELL CARCINOMA AND PROSTATE CANCER

Author

Biren Saraiya, Isaac Yi Kim, Brian Shinder, Sinae Kim, Thomas L. Jang, Tina M. Mayer, Hiren V. Patel, and Eric A. Singer

Subjects
Oncology, medicine.medical_specialty, business.industry, Urology, medicine.disease, Clinical trial, External validity, Prostate cancer, Renal cell carcinoma, Internal medicine, Medicine, Population study, business, human activities
Abstract

INTRODUCTION AND OBJECTIVE:A diverse and representative study population is critical to the external validity of oncologic clinical trials. In this regard, we sought to characterize factors associa...

Published
2021

7. MP16-14 CLINICAL OUTCOMES OF A RANDOMIZED, PROSPECTIVE, PHASE II STUDY TO DETERMINE THE EFFICACY OF BACILLUS CALMETTE-GUERIN (BCG) GIVEN IN COMBINATION WITH PANVAC VERSUS BCG GIVEN ALONE IN ADULTS WITH HIGH GRADE BCG-REFRACTORY NON-MUSCLE INVASIVE BLADDER CANCER

Author

Sonia Bellfield, Sammy Elsamra, Rebecca Dolan, Mahir Maruf, Piyush K. Agarwal, Cesar Pico Navarro, Thomas L. Jang, Beatriz Walter Rodriguez, Siobhan Telfer, Joanna Shih, Ragheed Saoud, James L. Gulley, Andrea B. Apolo, Eric A. Singer, Reema Railkar, Vladimir Valera, Renee Donohue, Jeffrey Schlom, Lambros Stamatakis, Maria J. Marino, Robert Weiss, and Sam J. Brancato

Subjects
Bacillus (shape), medicine.medical_specialty, Bladder cancer, biology, business.industry, Urology, Phases of clinical research, biology.organism_classification, medicine.disease, Gastroenterology, Refractory, Internal medicine, medicine, business, Non muscle invasive
Published
2021

8. MP45-16 THE IMPACT OF VENOUS THROMBOEMBOLISM PRESENCE AT THE TIME OF NEPHRECTOMY FOR RENAL MASS ON COMPLICATIONS, COSTS, AND SURVIVAL

Author

Arnav Srivastava, Isaac Yi Kim, Hiren V. Patel, Benjamin I. Chung, Joshua Sterling, Saum Ghodoussipour, Brian Shinder, Miral S. Grandhi, Eric A. Singer, Thomas L. Jang, Steven L. Chang, Saum Rahimi, and David A. August

Subjects
medicine.medical_specialty, business.industry, Urology, medicine.medical_treatment, Renal mass, medicine, business, Venous thromboembolism, Nephrectomy, Surgery
Published
2021

9. PD38-09 FACTORS ASSOCIATED WITH PALLIATIVE CARE UTILIZATION IN ADVANCED AND METASTATIC RENAL CELL CARCINOMA

Author

Brian Shinder, Eric A. Singer, Tina M. Mayer, Joshua Sterling, Isaac Yi Kim, Saum Ghodoussipour, Arnav Srivastava, Sinae Kim, Hiren V. Patel, Biren Saraiya, and Thomas L. Jang

Subjects
Oncology, medicine.medical_specialty, Palliative care, business.industry, Renal cell carcinoma, Urology, Internal medicine, Medicine, Cancer, business, medicine.disease
Abstract

INTRODUCTION AND OBJECTIVE:Palliative care (PC) offers various benefits for patient with cancer that include, but are not limited to, decrease in disease-specific symptoms and improvement in functi...

Published
2021

10. PD03-02 RACIAL DISPARITIES IN PROSTATE CANCER TREATMENT IN A MULTI-INSTITUTIONAL REGIONAL COLLABORATIVE

Author

Adrien Bernstein, Kaynaat Syed, Andres Correa, Ruchika Talwar, John Danella, Edouard J. Trabulsi, Robert G. Uzzo, Eric A. Singer, A. Kutikov, Jay D. Raman, Thomas J. Guzzo, Bruce L. Jacobs, Laurence Belkoff, Serge Ginzburg, Adam C. Reese, Elizabeth Handorf, Jeffery Tomaszewski, and Marc C. Smaldone

Subjects
2019-20 coronavirus outbreak, Prostate cancer, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), business.industry, Urology, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Pandemic, Medicine, business, medicine.disease, Intensive care medicine
Abstract

INTRODUCTION AND OBJECTIVE:Minority communities disproportionately shouldered poor COVID-19 outcomes, however the impact of the pandemic on prostate cancer (PCa) surgery is unknown. To that end, we...

Published
2021

11. MP43-16 CREATION AND VALIDATION OF PURC ACTIVE SURVEILLANCE ELIGIBILITY (PURCASE) SCORE: AN EMPIRICALLY DERIVED SCORING SYSTEM FOR DETERMINING ACTIVE SURVEILLANCE ELIGIBILITY

Author

Matthew Loecher, Jay D. Raman, Robert G. Uzzo, Edouard J. Trabulsi, Eric A. Singer, Serge Ginzburg, Bruce L. Jacobs, Kaynaat Syed, Cameron Rutledge, Thomas J. Guzzo, Laurence Belkoff, Jeffery Tomaszewski, Adam C. Reese, Chintan Mehta, and John Danella

Subjects
medicine.medical_specialty, Scoring system, business.industry, Urology, medicine, Medical physics, business
Published
2021

12. HF02-12 COLEY'S COCKTAIL: HOW WILLIAM B. COLEY BECAME THE FATHER OF IMMUNOTHERAPY

Author

Brian Shinder and Eric A. Singer

Subjects
medicine.medical_specialty, Genitourinary system, business.industry, Urology, medicine.medical_treatment, medicine, Immunotherapy, business, Dermatology
Abstract

INTRODUCTION AND OBJECTIVE:Immunotherapeutic agents now play a vital role in the treatment of genitourinary malignancies. Currently, there are multiple classes of these drugs that act to modulate t...

Published
2021

13. PD56-12 UTILIZATION OF MRI AND GENOMIC TESTS IN MEN WITH LOW-RISK PROSTATE CANCER AND A LIMITED LIFE EXPECTANCY WITHIN A MULTI-INSTITUTIONAL REGIONAL COLLABORATIVE

Author

Edouard J. Trabulsi, Chintan Mehta, Adrien Bernstein, Elizabeth Handorf, Serge Ginzburg, Eric A. Singer, Laurence Belkoff, Adam C. Reese, Laura C. Kidd, Kevin Ginsburg, Jay D. Raman, Jeffrey J. Tomaszewski, Bruce L. Jacobs, Thomas J. Guzzo, Kaynaat Syed, John Danella, and Marc C. Smaldone

Subjects
medicine.medical_specialty, Prostate cancer, business.industry, Urology, medicine.medical_treatment, medicine, Life expectancy, Intensive care medicine, business, medicine.disease, Watchful waiting, Ancillary test
Abstract

INTRODUCTION AND OBJECTIVE:Watchful waiting (WW) is the recommended management for men with low-risk prostate cancer (LRPC) and limited life expectancy (LLE). As such, the utility of ancillary test...

Published
2021

14. Editorial Comment

Author

Arnav Srivastava and Eric A. Singer

Subjects
Urology
Published
2021

15. MP11-12 ASSOCIATION OF LYMPH NODE COUNT AND SURVIVAL AFTER PRIMARY RETROPERITONEAL LYMPH NODE DISSECTION (RPLND) FOR TESTICULAR NONSEMINOMATOUS GERM CELL TUMOR (NSGCT)

Author

Arnav Srivastava, Eric A. Singer, Thomas L. Jang, Sinae Kim, Isaac Yi Kim, and Hiren V. Patel

Subjects
Retroperitoneal lymph node dissection, medicine.medical_specialty, medicine.anatomical_structure, business.industry, Urology, medicine.medical_treatment, medicine, Radiology, Stage (cooking), business, Single Center, Lymph node, Germ cell
Abstract

INTRODUCTION AND OBJECTIVE:RPLND for clinical stage (CS) I & IIA/B NSGCT has both staging and therapeutic implications. Single center studies have reported on the impact of lymph node count on outc...

Published
2020

16. MP20-07 CONCORDANCE BETWEEN MRI FUSION VS TRUS PROSTATE BIOPSY AND FINAL PATHOLOGY AT RADICAL PROSTATECTOMY: DATA FROM THE PURC

Author

Bret Marlowe, Ruchika Talwar, John Danella, Robert G. Uzzo, Aseem Malhotra, Edouard J. Trabulsi, Daniel J. Lee, Claudette Fonshell, Thomas J. Guzzo, Serge Ginzberg, Marc C. Smaldone, Eric A. Singer, Thomas Lanchoney, Bruce L. Jacobs, Jay D. Raman, Jeffrey J. Tomaszewski, and Katharine Michel

Subjects
medicine.medical_specialty, Prostate biopsy, medicine.diagnostic_test, Prostatectomy, business.industry, Urology, medicine.medical_treatment, Concordance, medicine, Radiology, business
Published
2020

17. MP14-20 IMPACT OF PATHOLOGIC NODE POSITIVE RENAL CELL CARCINOMA ON SURVIVAL IN PATIENTS WITHOUT METASTASIS: EVIDENCE IN SUPPORT OF EXPANDING THE DEFINITION OF STAGE IV KIDNEY CANCER

Author

Robert Weiss, Biren Saraiya, Arnav Srivastava, Isaac Yi Kim, Thomas L. Jang, Zorimar Rivera-Núñez, Nicholas J. Farber, Tina M. Mayer, Rahul R. Parikh, Parth K. Modi, Sinae Kim, Sharad Goyal, Eric A. Singer, Kushan D. Radadia, Joshua Sterling, and Sammy Elsamra

Subjects
Oncology, medicine.medical_specialty, business.industry, Urology, Node (networking), 030232 urology & nephrology, Disease, urologic and male genital diseases, medicine.disease, female genital diseases and pregnancy complications, Metastasis, 03 medical and health sciences, 0302 clinical medicine, Renal cell carcinoma, Internal medicine, medicine, In patient, Stage iv, business, Kidney cancer, Stage III Renal Cell Carcinoma
Abstract

INTRODUCTION AND OBJECTIVES:Stage III renal cell carcinoma (RCC) encompasses both node-positive (pT1-3N1M0) and node-negative (pT3N0M0) disease. However, prior institutional studies have indicated ...

Published
2019

18. MP43-01 PHASE 2 KEYNOTE-057 STUDY: PEMBROLIZUMAB FOR PATIENTS WITH HIGH-RISK NON–MUSCLE INVASIVE BLADDER CANCER UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN

Author

Tara L. Frenkl, Loic Mourey, Edward Uchio, Kijoeng Nam, Ronald de Wit, Ashish M. Kamat, Ekta Kapadia, Dean F. Bajorin, Joost L. Boormans, Badarinath Konety, Arjun Vasant Balar, Petros Grivas, Ho Kyung Seo, Girish S. Kulkarini, Eric A. Singer, Laurence Eliot Miles Krieger, and Hiroyuku Nishiyama

Subjects
Bacillus (shape), Oncology, medicine.medical_specialty, Bladder cancer, biology, business.industry, Urology, 030232 urology & nephrology, Pembrolizumab, biology.organism_classification, medicine.disease, complex mixtures, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Medicine, business, Non muscle invasive
Abstract

INTRODUCTION AND OBJECTIVES:Most patients with non-muscle invasive bladder cancer (NMIBC) who receive standard-of-care TURBT and Bacillus Calmette-Guerin (BCG) experience recurrence. For BCG-unresp...

Published
2019

19. MP84-12 OUTCOMES AND FACTORS ASSOCIATED WITH RECEIPT OF OPEN VS MINIMALLY INVASIVE RETROPERITONEAL LYMPH NODE DISSECTION (RPLND) FOR TESTIS CANCER: ANALYZING THE NATIONAL CANCER DATABASE (NCDB) FROM 2010-2014

Author

Isaac Yi Kim, Joshua Sterling, Sammy Elsamra, Kushan D. Radadia, Charles F. Polotti, Thomas L. Jang, Robert E. Weiss, Zorimar Rivera-Núñez, Parth K. Modi, Nicholas J. Farber, Alexandra L. Tabakin, Sharad Goyal, Rahul R. Parikh, Sinae Kim, and Eric A. Singer

Subjects
Receipt, Retroperitoneal lymph node dissection, medicine.medical_specialty, business.industry, Urology, medicine.medical_treatment, medicine, Cancer, Radiology, Testis cancer, medicine.disease, business
Published
2018

20. MP02-07 THE UROLOGY MATCH AND POST-INTERVIEW COMMUNICATION

Author

Christopher J. Neylan, Nicholas J. Farber, Eric A. Singer, Amy Kaplan, Kushan D. Radadia, and Sammy Elsamra

Subjects
medicine.medical_specialty, business.industry, Urology, Family medicine, Medicine, business
Published
2018

21. MP36-01 OUTCOMES OF LYMPHADENECTOMY FOR NON-METASTATIC RENAL CELL CARCINOMA: A PROPENSITY SCORE-WEIGHTED ANALYSIS

Author

Sharad Goyal, Eric A. Singer, Kushan D. Radadia, Robert Weiss, Thomas L. Jang, Nicholas J. Farber, Sinae Kim, Rahul R. Parikh, Sammy Elsamra, Zorimar Rivera-Núñez, Isaac Yi Kim, and Parth K. Modi

Subjects
Oncology, medicine.medical_specialty, business.industry, Renal cell carcinoma, Urology, Internal medicine, medicine.medical_treatment, Propensity score matching, Medicine, Non metastatic, Lymphadenectomy, business, medicine.disease
Published
2018

22. MP60-08 INTRACRINE ANDROGEN BIOSYNTHESIS IN RENAL CELL CARCINOMA

Author

Seok Joo Kwon, Young Suk Kwon, Wun-Jae Kim, Isaac Yi Kim, Geun Taek Lee, Hanjong Ahn, Eric A. Singer, Izak Faiena, Christopher Han, Parth K. Modi, Rutveej Patel, and Neal Patel

Subjects
Androgen biosynthesis, medicine.medical_specialty, Intracrine, Endocrinology, business.industry, Renal cell carcinoma, Urology, Internal medicine, medicine, business, medicine.disease
Published
2017

24. MP15-10 IMMUNOLOGIC RESPONSE TO A THERAPEUTIC CANCER VACCINE (PANVAC): INITIAL RESULTS FROM A RANDOMIZED PHASE 2 CLINICAL TRIAL

Author

Renee N. Donahue, Robert Weiss, Sammy Elsamra, James L. Gulley, Daniel Su, Yvonne Wall, Piyush K. Agarwal, Megan Anderson, Thomas Sanford, Jeffrey Schlom, Thomas L. Jang, Sonia Bellfield, Rebecca Dolan, Eric A. Singer, Sam J. Brancato, and Caroline Jochems

Subjects
Oncology, 03 medical and health sciences, medicine.medical_specialty, 0302 clinical medicine, business.industry, 030220 oncology & carcinogenesis, Urology, Internal medicine, 030232 urology & nephrology, medicine, Phases of clinical research, Cancer vaccine, business
Published
2017

25. MP12-17 ADRENALECTOMY FOR BENIGN AND MALIGNANT DISEASE: A POPULATION-BASED STUDY ON UTILIZATION AND OUTCOMES FROM 2003-2013

Author

Jeffrey J. Leow, Izak Faiena, Eric A. Singer, Alexandra L. Tabakin, Benjamin I. Chung, Amirali Salmasi, Neal Patel, Steven L. Chang, and Parth K. Modi

Subjects
Population based study, Oncology, medicine.medical_specialty, business.industry, Urology, Adrenalectomy, medicine.medical_treatment, Internal medicine, medicine, business, Malignant disease
Published
2016

27. MP09-13 OUTCOMES OF MEN WITH LOCALLY ADVANCED (LAPCA) OR REGIONALLY ADVANCED PROSTATE CANCER (RAPCA) FOLLOWING CONSERVATIVE MANAGEMENT (CM)

Author

Parth K. Modi, Isaac Yi Kim, Izak Faiena, Grace L. Lu-Yao, Robert S. DiPaola, Shunhua Shen, Thomas L. Jang, Neal Patel, Dirk F. Moore, and Eric A. Singer

Subjects
Oncology, medicine.medical_specialty, Prostate cancer, Conservative management, business.industry, Urology, Internal medicine, medicine, Locally advanced, business, medicine.disease
Published
2016

30. Editorial Comment

Author

Eric A. Singer, Parth K. Modi, and Evita T. Sadimin

Subjects
Urology
Published
2017

31. MP69-16 ACTIVE SURVEILLANCE FOR PROSTATE CANCER: RETHINKING PROSTATE-SPECIFIC ANTIGEN DENSITY ELIGIBILITY CRITERIA

Author

Isaac Yi Kim, Yun-Sok Ha, Jeong Hyun Kim, Neal Patel, Amirali Salmasi, Eric A. Singer, Wun-Jae Kim, and J. Yu

Subjects
Oncology, medicine.medical_specialty, medicine.diagnostic_test, business.industry, Urology, Disease, urologic and male genital diseases, medicine.disease, Gleason Score 6, Prostate cancer, Prostate-specific antigen, Cancer control, Internal medicine, Biopsy, medicine, business, neoplasms, Pathological
Abstract

However, no differences were observed in the BCR-free survival rates when patients with organ-confined disease and pathological Gleason score 6 (Group 1) were compared to those with organ-confined disease and pathological Gleason score 3+4 (Group 2; P1⁄40.4). CONCLUSIONS: Roughly a quarter of men of potential AS candidates harbors unfavorable disease at final pathology. While non organ confined and or Gleason score 4+3 patients had worse cancer control after RP, the upgrade from biopsy Gleason score 6 to pathological Gleason score 3+4 does not significantly increase the risk of BCR. Active therapy may be thus consider an overtreatment also in these men despite higher Gleason score (3+4). This may suggest the potential inclusion also of these men in prospective AS protocols.

Published
2014

34. ROBOTIC ASSISTED LAPAROSCOPIC TRANSVESICAL PROSTATECTOMY

Author

Allison Cardin, Melanie Butler, Fred Tonetti, Eric A. Singer, Louis Eichel, and John R. Valvo

Subjects
medicine.medical_specialty, Transvesical prostatectomy, Robotic assisted, business.industry, Urology, medicine, business, Surgery
Published
2009

35. LAPAROSCOPIC PELVIC LYMPHADENECTOMY WITH REAL TIME LYMPHATIC IMAGING USING NEAR INFRARED FLUORESCENCE (NIRF) CAMERAS

Author

Allison Cardin, Jay E. Reeder, Edward M. Messing, Dragan Golijanin, Ronald W. Wood, Jean V. Joseph, Eric A. Singer, Jonah Marshall, and Jorge L. Yao

Subjects
Agonist, medicine.medical_specialty, business.industry, medicine.drug_class, Urology, Urologic Oncology, urologic and male genital diseases, medicine.disease, Androgen, Surgery, Blockade, Metastasis, Androgen receptor, Prostate cancer, Quality of life, Medicine, business
Abstract

INTRODUCTION AND OBJECTIVE: Androgen ablation (AA) continues to be first line therapy for the treatment of metastatic prostate cancer (CaP). In the last decade, several recommendations have been made to modify AA therapy including the use of combinations of a GnRH agonist with an androgen receptor blocker (ARB) and the introduction of intermittent therapy. Yet it is unclear to what degree urologists have adopted these practices. To address this issue, we performed a survey of members of the Society of Urologic Oncology (SUO) to assess contemporary approaches in the use of AA in patients with metastatic CaP. METHODS: We sent surveys to 170 members of the SUO and received responses from nearly 50% after two rounds of inquiry. The concepts that were addressed included: use of complete simultaneous complete androgen blockade versus sequential blockade, use of intermittent therapy, PSA thresholds for initial therapy and for restarting therapy. RESULTS: The average time from the completion of the residency training was 15.8 years with 72% being fellowship-trained in oncology. The presence of metastasis and PSA doubling time were the most important factors in deciding on the initiation of AA. When primary treatment failed, doubling time less than 6 months was the most common threshold to start AA (66.7%). The use of PSA absolute value after failure primary treatment for starting AA varied significantly with cut-off numbers ranging between 0.4 and 100 ng/dl (median 10 ng/dl). The use of intermittent AA was noted in 84.8% of the questionnaires and was primarily motivated by a perception of improved quality of life in the patients (62.4%) rather than improved cancer-specific outcome (11.9%). ARBs are frequently used for an initial period 2 weeks upon starting GnRH agonists (64.6%) and added on if PSA started to rise while on GnRH agonist in 88.1%. Only, 15.6% of urologists utilize continuous combined androgen blockade mostly in settings of metastasis and high Gleason grades. Practice setting, fellowship training, and years out from training had no impact on responses. CONCLUSIONS: While sustained use of combined GnRH agonist and androgen receptor blocker was wildly herald a decade ago, sequential blockade is currently the preferred approach by most urologists for the treatment of metastatic CaP. Intermittent AA is a popular approach but its therapeutic value over continuous therapy remains to be determined. Threshold PSA values for initiation of therapy are highly variable and should be subjected to further study.

Published
2009

36. INFLUENCE OF SERUM TESTOSTERONE LEVEL AND BODY MASS INDEX ON SURVIVAL IN MEN TREATED WITH IMMEDIATE VERSUS DEFERRED ANDROGEN DEPRIVATION FOR NODE-POSITIVE PROSTATE CANCER AFTER PROSTATECTOMY AND PELVIC LYMPHADENECTOMY

Author

Judith Manola, Dragan Golijanin, Edward M. Messing, Ganesh S. Palapattu, Eric A. Singer, and Yu-Hui Chen

Subjects
Oncology, medicine.medical_specialty, Prostatectomy, medicine.drug_class, business.industry, Urology, Node (networking), medicine.medical_treatment, medicine.disease, Androgen, Serum testosterone level, Prostate cancer, Internal medicine, medicine, Pelvic lymphadenectomy, business, Body mass index
Published
2009

38. NEAR INFRARED FLUORESCENCE OF INTRAVENOUS INDOCYANINE GREEN FOR INTRAOPERATIVE IMAGING OF RENAL CORTICAL TUMORS: A COMPLETED FEASIBILITY STUDY

Author

Jonah Marshall, Allison Cardin, Guan Wu, Ronald W. Wood, Ralph Madeb, Dragan Golijanin, Jay E. Reeder, Jorge L. Yao, Edward M. Messing, and Eric A. Singer

Subjects
chemistry.chemical_compound, chemistry, business.industry, Urology, Medicine, Near infrared fluorescence, business, Nuclear medicine, Intraoperative imaging, Indocyanine green
Published
2008

39. BILITRANSLOCASE (BTL) IS IMMUNOLOCALISED IN PROXIMAL AND DISTAL RENAL TUBULES AND ABSENT IN RENAL CORTICAL TUMORS ACCURATELY CORRESPONDING TO INTRAOPERATIVE NEAR INFRARED FLUORESCENCE (NIRF) EXPRESSION OF RENAL CORTICAL TUMORS USING INTRAVENOUS INDOCYANINE GREEN (ICG)

Author

Jonah Marshall, Sabina Passamonti, Guan Wu, Allison Cardin, Jorge L. Yao, Dragan Golijanin, Jay E. Reeder, Edward M. Messing, Ronald W. Wood, Eric A. Singer, Golijanin, D. J., Marshall, J., Cardin, A., Singer, E. A., Wood, R. W., Reeder, J. E., Wu, G., Yao, J. L., Passamonti, Sabina, and Messing, E. M.

Subjects
Pathology, medicine.medical_specialty, Tumor, INTRAOPERATIVE NEAR INFRARED FLUORESCENCE, business.industry, Urology, Near infrared fluorescence, Kidney, Bilitranslocase, Indocyanin green, chemistry.chemical_compound, chemistry, Medicine, business, Indocyanine green
Abstract

386 BILITRANSLOCASE (BTL) IS IMMUNOLOCALISED IN PROXIMAL AND DISTAL RENAL TUBULES AND ABSENT IN RENAL CORTICAL TUMORS ACCURATELY CORRESPONDING TO INTRAOPERATIVE NEAR INFRARED FLUORESCENCE (NIRF) EXPRESSION OF RENAL CORTICAL TUMORS USING INTRAVENOUS INDOCYANINE GREEN (ICG) Dragan J Golijanin*, Jonah Marshall, Allison Cardin, Eric A Singer, Ronald W Wood, Jay E Reeder, Guan Wu, Jorge L Yao, Sabina Passamonti, Edward M Messing. Rochester, NY, and Trieste, Italy. INTRODUCTION AND OBJECTIVE: BTL is a 38 kDa

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results